Mylan N.V. (NASDAQ:MYL)‘s stock had its “buy” rating restated by UBS AG in a note issued to investors on Thursday, www.tipranks.com reports. They currently have a $46.00 price target on the stock. UBS AG’s price objective would indicate a potential upside of 21.69% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Citigroup Inc. raised Mylan N.V. from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $36.00 to $42.00 in a research report on Wednesday, August 16th. Mizuho reissued a “buy” rating and set a $37.00 price target (down previously from $53.00) on shares of Mylan N.V. in a research report on Sunday, August 20th. BMO Capital Markets reissued a “buy” rating and set a $45.00 price target on shares of Mylan N.V. in a research report on Friday, September 29th. ValuEngine raised Mylan N.V. from a “hold” rating to a “buy” rating in a research report on Monday. Finally, BTIG Research boosted their price target on Mylan N.V. from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Mylan N.V. has a consensus rating of “Buy” and an average target price of $42.04.

Shares of Mylan N.V. (NASDAQ:MYL) traded up 0.26% on Thursday, hitting $37.90. The stock had a trading volume of 8,903,641 shares. Mylan N.V. has a one year low of $29.39 and a one year high of $45.87. The firm’s 50 day moving average is $31.65 and its 200-day moving average is $36.47. The stock has a market capitalization of $20.33 billion, a PE ratio of 30.64 and a beta of 1.30. Mylan N.V. also was the recipient of unusually large options trading on Wednesday. Investors acquired 10,562 put options on the company. This is an increase of approximately 461% compared to the typical daily volume of 1,883 put options.

Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. Mylan N.V.’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period last year, the firm earned $1.16 EPS. Equities research analysts expect that Mylan N.V. will post $4.52 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/05/ubs-ag-reiterates-buy-rating-for-mylan-n-v-myl.html.

Hedge funds have recently modified their holdings of the stock. Global X Management Co. LLC boosted its stake in shares of Mylan N.V. by 91.6% in the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after buying an additional 1,441 shares during the period. TLP Group LLC bought a new stake in shares of Mylan N.V. in the first quarter valued at approximately $200,000. Doliver Capital Advisors LP bought a new stake in shares of Mylan N.V. in the second quarter valued at approximately $201,000. Eagle Global Advisors LLC bought a new stake in shares of Mylan N.V. in the second quarter valued at approximately $205,000. Finally, Sheaff Brock Investment Advisors LLC bought a new stake in shares of Mylan N.V. in the second quarter valued at approximately $210,000. Institutional investors and hedge funds own 71.97% of the company’s stock.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.